Watershed AC

Gene-editing technologies

Agriculture & Food Technologies
Private
Follow

Company Overview

Snapshot

Founded in August 2023, Watershed AC operates with 1–10 employees. The company has secured one funding round and received a grant from the Israel Innovation Authority in May 2024.

Business overview

Watershed AC is an Israel-based biotechnology company focused on sustainable aquaculture. The company develops advanced gene-editing technologies, such as CRISPR, to enhance crustacean traits including growth rate, disease resistance, and environmental adaptation. It operates within the Agriculture & Food Technologies sector, specifically targeting Ag Tech and Genetics & Input categories.

Strategic signal

In October 2024, Watershed AC, in collaboration with Evogene and Ben-Gurion University, received approval for a second-year grant from the Israel Innovation Authority. This continuation of their partnership aims to scale up CRISPR technology for industrial use in crustaceans, addressing limitations in gene editing for non-model organisms. This signals strong validation of their gene-editing approach and potential for significant advancements in sustainable aquaculture, particularly for the growing global shrimp and crayfish markets.

Log in to access full profile

Company Intelligence Q&A

What is Watershed AC's primary focus?
Watershed AC focuses on developing advanced gene-editing technologies, including CRISPR, to improve crustacean traits such as growth rate, disease resistance, and environmental adaptation for sustainable aquaculture.
When was Watershed AC founded?
Watershed AC was founded in August 2023.
Has Watershed AC received any grants?
Yes, in May 2024, Watershed AC received a grant from the Israel Innovation Authority.
What significant collaboration is Watershed AC involved in?
In October 2024, Watershed AC, Evogene, and Ben-Gurion University received approval for a second-year grant from the Israel Innovation Authority to continue their collaboration on developing CRISPR technology for crustaceans.
What is the goal of the collaboration with Evogene and Ben-Gurion University?
The collaboration aims to address limitations in gene editing for non-model organisms, focusing on improving traits like growth rate and disease resistance in crustaceans, with plans to scale the technology for industrial use.
Log in to access full profile